Advisory Committee To Decide If Azmacort, Alupent, Intal Remain "Essential" Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Pulmonary–Allergy Drugs Advisory Committee will be asked at July 14 meeting whether these and other asthma products provide an otherwise unavailable important public health benefit. Drugs using chlorofluorocarbon propellants could be delisted from essential use category if closely related non-CFC alternatives exist, even though they are not the same moiety, FDA suggests.
You may also be interested in...
FDA Advisory Committee Splits On Combivent “Essential Use” Designation
Pulmonary-Allergy Drugs Committee votes 5-5, with two abstentions, that Boehringer Ingelheim’s Combivent should retain “essential use” designation. King’s Intal gets committee nod for essential use by slim margin. Committee votes to remove essential use designation for five CFC metered-dose inhalers drugs.
FDA Advisory Committee Splits On Combivent “Essential Use” Designation
Pulmonary-Allergy Drugs Committee votes 5-5, with two abstentions, that Boehringer Ingelheim’s Combivent should retain “essential use” designation. King’s Intal gets committee nod for essential use by slim margin. Committee votes to remove essential use designation for five CFC metered-dose inhalers drugs.
CFC-Containing Albuterol Inhalers To Be Removed By 2009
FDA's final rule sets a deadline one year earlier than the latest possible date suggested in the proposed rule. Manufacturers have said that once a phase-out date was set they could build sufficient supply of ozone-friendly albuterol product within 18 months.